ROLE OF STATINS IN THE CORRECTION OF ENDOCRINE AND METABOLIC DISORDERS IN POLYCYSTIC OVARY SYNDROME

Objective. To evaluate the combined effects of a drospirenone-containing combination oral contraceptive (COC) versus atorvastatin with COC monotherapy on endocrine and metabolic parameters in patients with polycystic ovary syndrome. Subjects and methods. A prospective study enrolled 42 patients (mean age 23.9 year (range 20.25—27.0 years) with polycystic ovary syndrome, who were randomized into 2 groups: 1) 21 patients who were recommended to have combined therapy with a COC containing 30 μg ethinylestradiol, 3 mg drospirenone and atorvastatin 20 mg/day; 2) 21 patients who received COC monotherapy. Results. The additional use of atorvastatin enhances the antiandrogenic activity of COC, which is characterized by a statistically signif icant reduction in testosterone and and rostenedione levels and free androgen index and by an increase in testosterone-estrogen binding globulin. A combination of atorvastatin and COC has a positive effect on the blood lipid spectrum, which appears as a statistically significant drop in the levels of triglycerides, cholesterol, and low-density lipoproteins and atherogenicity coefficient. Both therapy options exert no negative impact on carbohydrate metabolic parameters, immunoreactive insulin levels, and insulin resistance. The combined therapy shows a 25% fall in the level of high-sensitivity C-reactive protein, one of the predictors of atherosclerosis development, which does not substantially change after COC therapy. Conclusion. The above changes suggest that combined therapy with COV and statins has a number of advantages over COC monotherapy in treating women with polycystic ovary syndrome.

polycystic ovary syndrome, statins, metabolic syndrome